palopegteriparatide
Commercial- Indications
- Hypoparathyroidism
Company intelligence / Profile preview
Specialised Therapeutics has successfully commercialized nine specialty products across oncology and other therapeutic areas. The company partners with global pharma/biotech firms to bring late-stage or approved therapies to market in Australia/NZ/SEA. Recent clinical results include a Phase 2 study of oregovomab for ovarian cancer showing improved outcomes when combined with chemotherapy[2].
6 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Specialised Therapeutics.